Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma

Sorafenib (Nexavar), a multiple kinase inhibitor, is the only clinically approved drug for patients with advanced HCC. However, its therapeutic success is limited by the emergence of drug resistance. Here we found that p21 and pGSK3β(Ser9) are major players in the resistance to sorafenib. We recentl...

詳細記述

保存先:
書誌詳細
主要な著者: Giovannini, Catia, Baglioni, Michele, Toaldo, Marco Baron, Ventrucci, Cristiano, D'Adamo, Stefania, Cipone, Mario, Chieco, Pasquale, Gramantieri, Laura, Bolondi, Luigi
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2013
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858550/
https://ncbi.nlm.nih.gov/pubmed/24113128
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料